Xenon Pharmaceuticals Inc

The metastatic prostate cancer market is projected to experience robust growth through 2036, valued at USD 11.5 billion in 2025 across seven major markets. The market is transitioning from conventional androgen deprivation therapy toward combination-based, biomarker-driven approaches, with novel therapies such as PSMA-targeted radioligand therapi...

Xenon Pharmaceuticals announced positive Phase 3 X-TOLE2 study results for azetukalner, a KV7 potassium channel opener for focal onset seizures, showing 53.2% reduction in monthly seizure frequency at 25mg versus 10.4% for placebo. Long-term data from the 48-month X-TOLE open-label extension study demonstrated nearly 40% of participants achieved ...

Xenon Pharmaceuticals' chief medical officer sold 1,410 shares worth $78,000 on March 13, 2026, representing a routine RSU vesting and sell-to-cover transaction. The stock has surged 55% following positive Phase 3 trial results for its lead candidate azetukalner and a $750 million capital raise. Despite significant losses ($345.9M in 2025), the w...

Xenon Pharmaceuticals priced an upsized public offering of 10.5 million common shares at $57.00 per share and pre-funded warrants, expected to raise approximately $650 million gross proceeds. The offering is expected to close on March 12, 2026, with J.P. Morgan, Jefferies, and other major underwriters managing the deal.

Commodore Capital increased its stake in Spyre Therapeutics by 400,161 shares ($10.46 million) in Q4, bringing its total position to $78.24 million (5.21% of AUM). SYRE stock has surged 63% over the past year, significantly outperforming the S&P 500's 13% gain. The preclinical biotech company, focused on inflammatory bowel disease treatments, has...